Markets:

Overview

News

Currencies

International

Treasuries

AtriCure, Inc. - Common Stock (NQ:ATRC)

38.63 -0.09 (-0.23%)

Streaming Delayed Price Updated: 9:30 AM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AtriCure, Inc. - Common Stock

< Previous 1 2 3 4 Next >

AtriCure Q2 Earnings Call Highlights ↗

July 23, 2026

AtriCure (NASDAQ:ATRC) reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management,...

Via MarketBeat

Topics Earnings

AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript ↗

July 23, 2026

AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you...

Via Benzinga

Topics Earnings

AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue ↗

July 23, 2026

Via Chartmill

AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook ↗

May 12, 2026

AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding...

Via MarketBeat

AtriCure (ATRC) Q1 2026 Earnings Transcript ↗

May 06, 2026

AtriCure (ATRC) Q1 2026 Earnings Transcript

Via The Motley Fool

AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestone ↗

May 05, 2026

Via Chartmill

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

AtriCure Inc (NASDAQ:ATRC) Stock Surges on Q4 2025 Earnings Beat and Profitability Milestone ↗

February 17, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

AtriCure Earnings Preview ↗

April 28, 2025

Via Benzinga

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching? ↗

March 18, 2026

This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns.

Via The Motley Fool

Topics Derivatives Regulatory Compliance

AtriCure (ATRC) Q4 2025 Earnings Call Transcript ↗

February 17, 2026

AtriCure (ATRC) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Earnings Scheduled For February 12, 2025 ↗

February 12, 2025

Via Benzinga

What's going on in today's pre-market session ↗

January 15, 2026

Via Chartmill

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares? ↗

November 29, 2025

This cardiac device maker focused on atrial fibrillation saw a notable insider sale following a year of flat share performance.

Via The Motley Fool

Topics Regulatory Compliance

AtriCure (ATRC) Q3 2025 Earnings Call Transcript ↗

October 30, 2025

AtriCure (ATRC) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

AtriCure Inc (NASDAQ:ATRC) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Outlook ↗

October 29, 2025

AtriCure's Q3 2025 earnings beat expectations with a narrowed loss and strong revenue growth. The medical device firm also raised its full-year financial outlook.

Via Chartmill

Topics Earnings

AtriCure (ATRC) Q2 2025 Earnings Call Transcript ↗

August 06, 2025

Via The Motley Fool

Topics Earnings

AtriCure (ATRC) Q2 Revenue Jumps 17% ↗

July 30, 2025

Via The Motley Fool

Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket ↗

July 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 29, 2025

Via Benzinga

What's going on in today's after hours session ↗

July 29, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

14 Analysts Assess AtriCure: What You Need To Know ↗

April 30, 2025

Via Benzinga

Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

April 30, 2025

Via Benzinga

11 Analysts Have This To Say About AtriCure ↗

March 21, 2025

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.